24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc., a promising biopharmaceutical enterprise focused on innovative therapeutic solutions, has opened trading today at $0.81, reflecting a decline to $0.772, or approximately 1.91%, following the previous session’s close at $0.787. This downturn points to a bearish trend, underscored by a notable trading volume of 8.16 million shares, indicating heightened investor activity. Technical analysis reveals possible resistance at the $0.79 level, while any further dip below recent lows could suggest an extended downside. Investors are advised to stay vigilant regarding price movements and volume fluctuations as they might indicate a potential reversal or continuation of the prevailing trend.

In a significant development for the company, Hoth Therapeutics has secured an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA), in partnership with Emory University. This agreement centers around groundbreaking research related to Glial Cell Line-Derived Neurotrophic Factor and its potential applications in addressing obesity and associated health issues. By bolstering its intellectual property portfolio with this strategic partnership, Hoth positions itself as a key player in the obesity treatment arena.

Robb Knie, CEO of Hoth Therapeutics, emphasized the importance of the collaboration, stating, “We are honored to collaborate with esteemed institutions like the VA and Emory University. This partnership marks a significant milestone in our commitment to combating obesity through science-driven solutions.” Furthermore, Hoth aims to expand the application of its leading therapeutic, HT-001, through a new Letter of Intent (LOI), broadening its oncology impact.

This innovative collaboration solidifies Hoth Therapeutics’ strategy for partnership development and underscores its dedication to transforming scientific research into impactful healthcare advancements. As the company progresses, its commitment to enhancing patient outcomes remains paramount.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.